What is ATHE's current stock price?

ATHE (Alterity Therapeutics Limited) is currently trading at $4.14 with a market cap of $37.5M.

What sector is Alterity Therapeutics Limited in?

Alterity Therapeutics Limited (ATHE) operates in the Healthcare sector, specifically in the Biotechnology industry.

InvestLog

ATHE Alterity Therapeutics Limited

Healthcare

$4.14-0.96%ClosedMarket Cap: $37.5M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

1.69

P/S

25.54

EV/EBITDA

-2.43

DCF Value

$-10.96

FCF Yield

-2.4%

Div Yield

0.0%

Margins & Returns

Gross Margin

96.8%

Operating Margin

-525.6%

Net Margin

-380.7%

ROE

-30.2%

ROA

-25.6%

ROIC

-31.3%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$0.00	$-9.4M	$—
Q4 null	$3.8M	$-5.0M	$—
FY null	$5.4M	$-12.1M	$—
Q2 null	$1.6M	$-7.2M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell

Trading Activity

Insider Trades

View All

Cunningham Ann Michelledirector:

SellWed Apr 29

Stamler David Allendirector, officer: Chief Executive Officer

SellWed Apr 15

Stamler David Allendirector, officer: Chief Executive Officer

SellWed Apr 15

Stamler David Allendirector, officer: Chief Executive Officer

SellWed Apr 15

Stamler David Allendirector, officer: Chief Executive Officer

SellWed Apr 15

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.34

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Peers

IGC